Personalized support and navigation increased genetic testing of hereditary cancers among immediate family members
Relatives of cancer patients who received guidance and support from navigators were more likely to complete genetic testing for hereditary cancers, study finds
Trial tested for BRCA1 and BRCA2 gene mutations, which are linked to elevated risks of multiple cancers
Personalized support increased BRCA genetic testing among at-risk family members; by 18 months, 90% of relatives in facilitated testing group had completed genetic testing
...
Study identifies two factors that may help patients benefit from off-the-shelf CAR T cell therapies
While approved CAR T cell therapies are made from a patient's own cells, off-the-shelf CAR T cell therapies are manufactured from healthy donor...
Hodgkin lymphoma survivors face twice the risk of death compared to average American adult
Adults who survive Hodgkin lymphoma (HL) for at least five years face increased risk of death from non-cancer conditions and cardiovascular...
Donor cord blood composition may influence CAR NK cell therapy outcomes
CAR NK cell therapy is a novel immunotherapy made from natural killer (NK) cells engineered to better recognize and eliminate cancer cells
At UT MD Anderson, CAR NK cell therapies are created from NK cells collected from donated umbilical cord blood
UT MD Anderson researchers identified a small population of immature NK cells associated with poorer treatment outcomes
These immature cells can pick up cancer proteins through a process...
Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL
Seventy percent of patients had residual levels of cancer cells eliminated
Clearing residual cancer cells is a strong predictor...
UT MD Anderson joins global consortium committed to eliminating cervical cancer
The University of Texas MD Anderson Cancer Center today announced it has joined a global consortium dedicated to accelerating the elimination...
Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies
The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas
UT MD Anderson received Investigational New Drug clearance from the...
Low-intensity combination therapy yields strong outcomes in hard-to-treat AML
Researchers combined an alternating regimen of lower-intensity therapy with a targeted agent in older or medically fragile patients with newly...
Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphoma
Phase 2 trial evaluated abbreviated chemotherapy plus brentuximab vedotin and nivolumab
Combination achieved complete response in&...
FLAG-based regimen delivers strong outcomes in subtype of acute myeloid leukemia
Highest reported five-year, relapse-free survival and overall survival rates, especially with FLAG-GO
<...